Patents by Inventor Nicola TUFILLI

Nicola TUFILLI has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 8809340
    Abstract: This invention relates to a new crystalline form of the succinate salt of the epithelial sodium channel (ENaC) blocker 3-(3-{2-[(E)-3,5-Diamino-6-chloro-pyrazine-2-carbonylimino]-1,3,8-triaza-spiro[4.5]decane-8-carbonyl}-benzenesulfonylamino)-propionic acid dipropylcarbamoylmethyl ester, pharmaceutical compositions comprising said crystalline form, uses of said crystalline form and pharmaceutical compositions, and methods for preparing said crystalline form.
    Type: Grant
    Filed: March 12, 2013
    Date of Patent: August 19, 2014
    Assignee: Novartis AG
    Inventors: Catherine Howsham, Christian Lindenberg, Anett Perlberg, Nicola Tufilli
  • Publication number: 20140128370
    Abstract: The invention relates to substituted tetrahydro-pyrido-pyrimidine derivatives of the formula (I), wherein Y, R1, R2 and m are as defined in the description. Such compounds are suitable for the treatment of a disorder or disease which is mediated by the activity of the PI3K enzymes.
    Type: Application
    Filed: January 9, 2014
    Publication date: May 8, 2014
    Applicant: NOVARTIS AG
    Inventors: Nigel Graham COOKE, Frédéric ZECRI, Nicolas SOLDERMANN, Romain WOLF, Christina HEBACH, Klemens HOEGENAUER, Gregory John HOLLINGWORTH, Anette VON MATT, Ross Sinclair STRANG, Alexander Baxter SMITH, Paulo FERNANDES GOMES DOS SANTOS, Nadege GRAVELEAU, Frank STOWASSER, Nicola TUFILLI
  • Patent number: 8653092
    Abstract: The invention relates to substituted tetrahydro-pyrido-pyrimidine derivatives of the formula (I), wherein Y, R1, R2 and m are as defined in the description. Such compounds are suitable for the treatment of a disorder or disease which is mediated by the activity of the PI3K enzymes.
    Type: Grant
    Filed: July 1, 2011
    Date of Patent: February 18, 2014
    Assignee: Novartis AG
    Inventors: Nigel Graham Cooke, Paulo Fernandes Gomes Dos Santos, Nadege Graveleau, Christina Hebach, Klemens Högenauer, Gregory Hollingworth, Alexander Baxter Smith, Nicolas Soldermann, Frank Stowasser, Ross Strang, Nicola Tufilli, Anette Von Matt, Romain Wolf, Frédéric Zecri
  • Publication number: 20130345239
    Abstract: This invention relates to a new crystalline form of the succinate salt of the epithelial sodium channel (ENaC) blocker 3-(3-{2-[(E)-3,5-Diamino-6-chloro-pyrazine-2-carbonylimino]-1,3,8-triaza-spiro[4.5]decane-8-carbonyl}-benzenesulfonylamino)-propionic acid dipropylcarbamoylmethyl ester, pharmaceutical compositions comprising said crystalline form, uses of said crystalline form and pharmaceutical compositions, and methods for preparing said crystalline form.
    Type: Application
    Filed: March 12, 2013
    Publication date: December 26, 2013
    Inventors: Catherine Howsham, Christian Lindenberg, Anett Perlberg, Nicola Tufilli
  • Publication number: 20130245080
    Abstract: The present invention provides a compound of formula (I) in free form or in pharmaceutically acceptable salt form a method for manufacturing the compound of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and pharmaceutical compositions.
    Type: Application
    Filed: September 5, 2012
    Publication date: September 19, 2013
    Applicant: NOVARTIS AG
    Inventors: Jun CAO, Bernhard ERB, Robin Alec FAIRHURST, Arnaud GRANDEURY, Shinji HATAKEYAMA, Magdalena KOZICZAK-HOLBRO, Xinzhong LAI, Philipp LUSTENBERGER, Bernd RIEBESEHL, Nicola TUFILLI, Thomas ULLRICH, Xiang WU, Jianguang ZHOU
  • Publication number: 20120065183
    Abstract: The invention relates to substituted tetrahydro-pyrido-pyrimidine derivatives of the formula (I), wherein Y, R1, R2 and m are as defined in the description. Such compounds are suitable for the treatment of a disorder or disease which is mediated by the activity of the PI3K enzymes.
    Type: Application
    Filed: July 1, 2011
    Publication date: March 15, 2012
    Applicant: NOVARTIS AG
    Inventors: Nigel Graham COOKE, Paulo FERNANDES GOMES DOS SANTOS, Nadege GRAVELEAU, Christina HEBACH, Klemens HOEGENAUER, Gregory John HOLLINGWORTH, Alexander Baxter SMITH, Nicolas SOLDERMANN, Frank STOWASSER, Ross STRANG, Nicola TUFILLI, Anette VON MATT, Romain WOLF, Frédéric ZECRI